butenafine
Trade name: mentax
Approved
Oct 18, 1996
Butenafine is a synthetic antifungal agent that is structurally and pharmacologically related to allylamine antifungals. The exact mechanism of action has not been established, but it is suggested that butenafine's antifungal activity is exerted through the alteration of cellular membranes, which results in increased membrane permeability, and growth inhibition. Butenafine is mainly active against dermatophytes and has superior fungicidal activity against this group of fungi when compared to that of terbinafine, naftifine, tolnaftate, clotrimazole, and bifonazole. It is also active against Candida albicans and this activity is superior to that of terbinafine and naftifine. Butenafine also generates low MICs for Cryptococcus neoformans and Aspergillus spp. as well. Butenafine hydrochloride is marketed under the trade names Mentax, Butop (India) and is the active ingredient in Lotrimin Ultra. MENTAX Cream, 1%, is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (formerly Pityrosporum orbiculare). Although the mechanism of action has not been fully established, it has been suggested that butenafine, like allylamines, interferes with sterol biosynthesis (especially ergosterol) by inhibiting squalene monooxygenase, an enzyme responsible for converting squalene to 2,3-oxydo squalene. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Blockage of squalene monooxygenase also leads to a subsequent accumulation of squalene. When a high concentration of squalene is reached, it is thought to have an effect of directly kill fungal cells. Butenafine cream 1% is indicated in treatment of tinea pedis, tinea corporis and tinea cruris. In tinea pedis it is recommended twice daily for 7 days or once daily for 4 weeks. In tinea cruris and tinea corporis it is recommended once daily for two weeks. — NCATS
Clinical trial activity
10 trials · 8 clinical orgs · 4 marketing orgs
Earliest trial started Jun 1, 2008 (NCT00835510)
Timeline
2000s
- Dec 7, 2001
Bayer — NDA Secondary Org
- Jan 1, 2008
Taro Pharmaceuticals — Earliest Phase 1 Sponsor(trial)
2010s
- Jan 1, 2013
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
- Nov 16, 2017
Taro Pharmaceuticals — Marketing Organization
- Nov 16, 2017
Sun Pharmaceuticals — Marketing Organization
Indications
Approved for
Mechanism of action
- Squalene monooxygenaseINHIBITOR
Squalene monooxygenase inhibitor
Approval history
- approvedOct 18, 1996
Chemistry & pharmacology
SMILES
CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12- Mol. weight
- 317.48 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Over the Counter
Oral
No
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL990 ↗
- WikipediaButenafine ↗
- NCATS91Y494NL0X ↗
- ChEMBLCHEMBL1200397 ↗
Also known as
- 4-tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine
- 4-tert-butylbenzyl(methyl)(1-naphthalenemethyl)amine
- (4-tert-butyl-benzyl)-methyl-naphthalen-1-ylmethyl-amine
- (4-tert-butyl-benzyl)-methyl-naphthalen-1-ylmethyl-amine
- (4-tert-butylphenyl)-n-methyl-n-(naphthalen-1-ylmethyl)methanamine
- (4-tert-butylphenyl)-n-methyl-n-(naphthalen-1-ylmethyl)methanamine
- butenafina
- butenafina
- butenafine
- butenafine
- butenafine
- butenafine
- butenafine
- butenafine
- butenafine
- butenafine
- butenafine
- butenafine hcl
- butenafine hcl
- butenafine hcl
- butenafine hydrochloride
- butenafine hydrochloride
- butenafine hydrochloride
- butenafine hydrochloride
- butenafine hydrochloride
- butenafinum
- butenafinum
- kp 363
- kp 363
- kp-363
- kp-363
- kp-363
- kp-363
- lotrimin ultra
- lotrimin ultra
- mentax
- mentax
- mentax
- mentax
- mentax-tc
- mentax-tc
- n-4-tert-butylbenzyl-n-methyl-1-naphthalene methylamine hydrochloride
- n-(p-tert-butylbenzyl)-n-methyl-1-naphthalenemethylamine
- n-(p-tert-butylbenzyl)-n-methyl-1-naphthalenemethylamine
- s2g6t
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03999437 | Phase 2 | Jan 2, 2019 | United Laboratories Inc |
| NCT02842021 | Phase 2 | Sep 1, 2016 | Cu-Tech, Sol-Gel Technologies, Ltd. |
| NCT01990092 | N/A | Nov 30, 2013 | Harvard University, Pamlab |
| NCT04531540 | Phase 3 | Sep 9, 2013 | Bayer |
| NCT04531527 | Phase 3 | Jun 24, 2013 | Bayer |
| NCT04531813 | Phase 3 | Jun 10, 2013 | Bayer |
| NCT04532164 | Phase 3 | Jun 10, 2013 | Bayer |
| NCT01580878 | Phase 1 | Jan 1, 2012 | Symbio, Taro Pharmaceuticals |
| NCT01119742 | Phase 1 | Jul 1, 2010 | Taro Pharmaceuticals |
| NCT00835510 | Phase 1 | Jun 1, 2008 | Taro Pharmaceuticals |
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 4 | 4 | 1 | 2013 |
| Taro Pharmaceuticals | For profit | 3 | 3 | 1 | 2008 |
| Cu-Tech | For profit | 1 | 0 | 1 | 2016 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Pamlab | For profit | 1 | 1 | 1 | 2013 |
| Sol-Gel Technologies, Ltd. | For profit | 1 | 1 | 1 | 2016 |
| Symbio | For profit | 1 | 0 | 1 | 2012 |
| United Laboratories Inc | For profit | 1 | 1 | 1 | 2019 |
Marketing (6)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bayer | For profit | NDA2 | Dec 7, 2001 |
| Mylan | For profit | SYN | Oct 18, 1996 |
| Mylan | For profit | NDA | Oct 18, 1996 |
| Sun Pharmaceuticals | For profit | MKTG | Nov 16, 2017 |
| Taro Pharmaceuticals | For profit | SYN | Nov 16, 2017 |
| Taro Pharmaceuticals | For profit | MKTG | Nov 16, 2017 |